5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

Srinivasan, Ramprasad; Su, Dong-Na; Stamatakis, Lambros; Siddiqui, Marium; Singer, Eric A.; Shuch, Brian; Nix, Jeffrey; Friend, Judith; Hawks, Geri; Shih, Jin‐Yuan; Choyke, Peter; Linehan, W. Marston

doi:10.1016/s0959-8049(14)70131-5

Cited by 37 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They were treated with bevacizumab and erlotinib. 16 The HLRCC group showed a median PFS of 24.2 months and ORR of 60%. Sporadic cases showed median PFS of 7.4 months and ORR of 29%.…”

Section: Bevacizumab and Erlotinib For Advanced Papillary Rcc Includimentioning

confidence: 92%

Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

Sengupta

Basu

Ghosh³

2020

Int J Adv Med

View full text Add to dashboard Cite

Non-clear cell renal cell carcinoma (nccRCC) is not as common as clear cell renal cell carcinoma (ccRcc). But then it is not uncommon in regular urological practice. It usually carries a grave prognosis. Authors need to converse ourselves with National comprehensive cancer network (NCCN) categories for evidence and we need to converse as well with NCCN categories for preferences. ‘Preferred intervention’ is based on superior efficacy, safety and evidence and when appropriate, affordability. ‘Other recommended interventions’ are somewhat less efficacious, more toxic, or based on less mature data or significantly less affordable for similar outcomes. ‘Useful in certain circumstances’ are interventions that may be used for a selected patient population. Clinical trials for targeted agents are mainly directed at ccRCC because of its high prevalence. According to the NCCN panel, enrolment in clinical trials is the preferred strategy for nccRCC. Outcomes of patients with nccRCC have improved with the introduction of targeted therapy. Precise pathological diagnosis of the types of nccRCC by immunohistochemical analysis is mandatory. This enables specific treatments for individual nccRCC. Currently TKIs are the drug of choice (both first and second line) for metastatic papillary RCC. Both TKIs and mTOR inhibitors are effective against chromophobe RCC. Platinum based chemotherapy should be used for metastatic CDC. Further evidence is required for management of nccRCC.

show abstract

“…They were treated with bevacizumab and erlotinib. 16 The HLRCC group showed a median PFS of 24.2 months and ORR of 60%. Sporadic cases showed median PFS of 7.4 months and ORR of 29%.…”

Section: Bevacizumab and Erlotinib For Advanced Papillary Rcc Includimentioning

confidence: 92%

Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

Sengupta

Basu

Ghosh³

2020

Int J Adv Med

View full text Add to dashboard Cite

show abstract

“…Bevacizumab, a humanized monoclonal antibody that binds VEGF, was tested in addition to erlotinib (an epidermal growth factor receptor inhibitor) in a phase II trial (Stamatakis et al 2011) and updated at the 2014 European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Symposium. The median PFS time was 7 months for patients with sporadic disease, and the ORR was approximately 30% among all patients (Srinivasan 2014).…”

Section: Papillary Renal Carcinomamentioning

confidence: 99%

Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

Soares

Monteiro

Maluf

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The outcome of RCC has improved considerably in the last few years, and the treatment options have increased. LACOG-GU and LARCG held a consensus meeting to develop guidelines to support the clinical decisions of physicians and other health professionals involved in the care of RCC patients. Methods Eighty questions addressing relevant advanced RCC treatments were previously formulated by a panel of experts. The voting panel comprised 26 specialists from the LACOG-GU/LARCG. Consensus was determined as 75% agreement. For questions with less than 75% agreement, a new discussion was held, and consensus was determined by the majority of votes after the second voting session. Results The recommendations were based on the highest level of scientific evidence or by the opinion of the RCC experts when no relevant research data were available. Conclusion This manuscript provides guidance for advanced RCC treatment according to the LACOG-GU/LARCG expert recommendations.

show abstract

“…Other ongoing trials in pRCC include phase 2 studies of selective Met inhibitors, including INC280 and AZD6094, and the combination of the EGFR inhibitor erlotinib with bevacizumab [59], as summarized in Table 4.…”

Section: The State Of Treatment For Non-clear Cell Rccmentioning

confidence: 99%

Renal cell carcinoma: molecular characterization and evolving treatment paradigms

Ball¹,

Singer

Srinivasan

2017

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review The treatment landscape of advanced renal cell carcinoma (RCC) continues to shift as both new targeted therapies and immunotherapies show efficacy in treating the disease. Contemporary insights into the molecular characterization of RCC are likely to fuel the development of additional therapies. This review summarizes recent advancements in the biologic characterization of RCC and discusses newly approved therapies and ongoing studies in the treatment of advanced RCC. Recent findings The Cancer Genome Atlas has now completed comprehensive molecular characterization of clear cell, papillary and chromophobe RCC, providing insights into the biology of these entities. Two new ‘targeted’ therapies, cabozantinib and lenvatinib, as well as a novel immune checkpoint inhibitor, the PD-1 inhibitor nivolumab, have recently been approved for the treatment of metastatic RCC. Although some of these newer therapies are associated with prolongation of survival, there are few long-term responders and the quest for more durable treatment strategies continues. Summary The addition of several new agents effective in metastatic renal cell carcinoma has resulted in improvements in overall survival; however, there are few avenues to durable responses or cure. Ongoing studies as well advances in our understanding of the molecular alterations underlying distinct forms of RCC promise further therapeutic advances and have the potential to alter the current treatment paradigm.

show abstract

5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

Cited by 37 publications

References 0 publications

Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

Renal cell carcinoma: molecular characterization and evolving treatment paradigms

Contact Info

Product

Resources

About